Characterization, Quantification and Pharmacokinetic Analysis of Bevacizumab and Its Glycosylation by Mass Spectrometry

doi:10.11895/j.issn.0253-3820.170170

	Characterization, Quantification and Pharmacokinetic Analysis of Bevacizumab and Its Glycosylation by Mass Spectrometry
	Ye Ming-Liang 2; Zou Han-Fa 2; Cong Yu-Ting 1,2; Hu Liang-Hai 1; Gu Jing-Kai 1
刊名	CHINESE JOURNAL OF ANALYTICAL CHEMISTRY
	2017-11-01
卷号	45 期号:11 页码:1678-1685
关键词	Bevacizumab Glycosylation Liquid Chromatography-tandem Mass Spectrometry Parallel Reaction Monitoring Pharmacokinetics
ISSN号	0253-3820
DOI	10.11895/j.issn.0253-3820.170170
文献子类	Article
英文摘要	The bevacizumab and its glycoforms were analyzed by matrix-assisted laser desorption ionization time of flight-time of flight-mass spectrometry (MALDI-TOF-MS), sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and short-gun strategy, with the sequence of unique peptide and seventeen glycoforms being characterized. The bevacizumab and its glycopeptides concentrations in mice plasma with different intravenous injection doses of bevacizumab were detected and the concentration-time curves were obtained by parallel reaction monitoring (PRM) method based on liquid chromatography-tandem mass spectrometry (LC-MS/MS) technique. First, standard curves were created for quantification of mAb in mice plasma, which showed good linearity, with the correlation coefficient (R-2) value of 0.998 and the lower limit of quantification of 66 fmol. Detection results of high and low doses of the drug in the mice plasma samples showed that the drug concentration-time curve trend was consistent, e.g. the concentration was decreasing. However, the results of quantitation of seventeen glycoforms demonstrated that the metabolism of different glycoforms was different. The concentrations of most glycoforms increased first, whereas the metabolism afterwards differed by different glycoforms.
WOS关键词	THERAPEUTIC ANTIBODIES ; IMMUNOGLOBULIN-G ; QUANTITATION ; PROTEOMICS ; MS
WOS研究方向	Chemistry
语种	英语
出版者	ELSEVIER SCIENCE INC
WOS记录号	WOS:000419177900011
内容类型	期刊论文
源URL	[http://cas-ir.dicp.ac.cn/handle/321008/169244]
专题	大连化学物理研究所_中国科学院大连化学物理研究所
通讯作者	Hu Liang-Hai
作者单位	1.Jilin Univ, Coll Life Sci, Changchun 130012, Jilin, Peoples R China 2.Chinese Acad Sci, Dalian Inst Chem Phys, CAS Key Lab Separat Sci Analyt Chem, Natl Chromatog R&A Ctr, Dalian 116023, Peoples R China
推荐引用方式 GB/T 7714	Ye Ming-Liang,Zou Han-Fa,Cong Yu-Ting,et al. Characterization, Quantification and Pharmacokinetic Analysis of Bevacizumab and Its Glycosylation by Mass Spectrometry[J]. CHINESE JOURNAL OF ANALYTICAL CHEMISTRY,2017,45(11):1678-1685.
APA	Ye Ming-Liang,Zou Han-Fa,Cong Yu-Ting,Hu Liang-Hai,&Gu Jing-Kai.(2017).Characterization, Quantification and Pharmacokinetic Analysis of Bevacizumab and Its Glycosylation by Mass Spectrometry.CHINESE JOURNAL OF ANALYTICAL CHEMISTRY,45(11),1678-1685.
MLA	Ye Ming-Liang,et al."Characterization, Quantification and Pharmacokinetic Analysis of Bevacizumab and Its Glycosylation by Mass Spectrometry".CHINESE JOURNAL OF ANALYTICAL CHEMISTRY 45.11(2017):1678-1685.